Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Endocrinology · Immunotherapy-Induced Hypophysitis

Understanding Immunotherapy-Induced Hypophysitis

At a Glance

Immunotherapy-induced hypophysitis is pituitary inflammation that can reduce hormone production, especially cortisol. Blood tests diagnose hormone deficiencies, MRI may be normal, and long-term replacement plus sick-day planning can help prevent a dangerous adrenal crisis.

Receiving a diagnosis of hypophysitis (inflammation of the pituitary gland) while you are already fighting cancer can feel like an overwhelming setback. It is a chronic condition that often requires long-term management, and it is natural to feel frustrated that your treatment for one illness has created another [1][2]. However, with proper hormone replacement, most people are able to stabilize their symptoms and, in many cases, continue the immunotherapy that is working against their cancer [3][4].

What is Immunotherapy-Induced Hypophysitis?

Your pituitary gland is a pea-sized organ at the base of your brain, which sends signals to other organs (like your adrenal glands and thyroid) to produce essential hormones [5]. Hypophysitis is inflammation of this gland caused by your immune system.

Immunotherapy drugs called Immune Checkpoint Inhibitors (ICIs) work by “taking the brakes off” your immune system so it can find and attack cancer cells. Sometimes, this newly activated immune system also attacks healthy tissue in the pituitary gland [6]. This attack can damage the cells that produce hormones, leading to a drop in hormone levels that your body needs to function properly [7].

Why This Happens

The exact reason the immune system targets the pituitary gland is still being studied, but researchers are investigating several hypotheses:

  • Direct Expression: Some pituitary cells may actually have the same “checkpoint” proteins (like CTLA-4) that the drugs are designed to target, making the gland an accidental target for the immune system [6].
  • Antibody Attack: In some patients, the immune system might create antibodies (proteins that mark targets for destruction) that specifically attack pituitary cells, though testing for these is not currently a routine part of diagnosis [8].
  • T-Cell Activation: Activated immune cells (T-cells) may infiltrate the gland, causing inflammation and swelling [9].

Risk and Incidence

The likelihood of developing hypophysitis depends heavily on which type of immunotherapy you are receiving. Based on pooled estimates from clinical studies:

Immunotherapy Type Common Drug Names Estimated Risk of Hypophysitis
CTLA-4 Inhibitors Ipilimumab (Yervoy) ~5.6% [10]
PD-1 Inhibitors Nivolumab (Opdivo), Pembrolizumab (Keytruda) ~0.5% – 1.1% [10]
Combination Therapy Ipilimumab + Nivolumab ~8.8% – 10.5% [10][11]

Comparing Different Drugs

The way hypophysitis shows up can vary based on the drug:

  • CTLA-4 Inhibitors: These tend to cause symptoms earlier (often after the 2nd or 3rd dose) and are more likely to cause physical swelling of the gland that can be seen on an MRI [5][12]. They often affect multiple hormone systems at once [13].
  • PD-1/PD-L1 Inhibitors: These often cause symptoms much later (sometimes after 6 months of treatment) [5]. The gland rarely swells, so an MRI might look completely normal even if the gland is not working [14]. They often cause an “isolated” deficiency, meaning only one hormone (usually ACTH, which controls cortisol) is affected [7].

Signs and Symptoms

Because the pituitary gland controls so many functions, the symptoms can be broad and sometimes easy to mistake for general cancer fatigue or “feeling under the weather.”

  • Fatigue and Weakness: This is often the most common symptom, caused by low cortisol levels [5].
  • Headaches: Caused by inflammation or swelling of the gland [15].
  • Nausea and Loss of Appetite: These can be signs of secondary adrenal insufficiency (when the pituitary stops telling the adrenals to make cortisol) [16].
  • Confusion or Dizziness: Especially when standing up, due to changes in blood pressure or salt levels [15][17].

Diagnosis and Imaging

To diagnose hypophysitis, your doctor will use a combination of blood tests and imaging:

  1. Hormone Panels: You will likely have blood drawn in the early morning to check levels of ACTH, cortisol, Free T4 (to monitor thyroid axis), and others [18][19].
  2. MRI: A contrast-enhanced MRI of the sella (the bony pocket where the pituitary sits) can show if the gland is enlarged or if the “stalk” is thickened [20]. However, as noted above, a normal MRI does not rule out the condition, especially if you are on a PD-1 inhibitor [14][21].

Living with Hypophysitis

If your pituitary gland is damaged, it often cannot recover its ability to produce hormones, particularly ACTH (cortisol) [2][22]. This means you will likely need to take daily hormone replacement pills for the foreseeable future.

The Importance of “Sick Day Rules”

When you have adrenal insufficiency, your body cannot produce the extra cortisol needed to handle physical stress. You must follow sick day rules, which involve increasing your steroid dose (usually hydrocortisone) during times of:

  • Fever or infection [23]
  • Severe injury or dental/surgical procedures [24]
  • Persistent vomiting or diarrhea (which prevents you from absorbing your pills) [23][25]

Adrenal Crisis Warning: If you cannot keep your medication down or feel severely confused, weak, or faint, this is a medical emergency called an adrenal crisis. You must seek immediate medical attention and tell the responders you have adrenal insufficiency [16][26].

Common questions in this guide

What exactly happens when immunotherapy causes hypophysitis?
Immunotherapy-induced hypophysitis is inflammation of the pituitary gland caused by an immune response to an immune checkpoint inhibitor. The inflammation can damage hormone-producing cells, particularly those involved in signaling the adrenal glands to make cortisol.
Which cancer immunotherapy drugs have the greatest risk of hypophysitis?
The risk is highest with CTLA-4 inhibitors such as ipilimumab and with combination therapy such as ipilimumab plus nivolumab. It is lower with PD-1 inhibitors such as nivolumab and pembrolizumab, although these drugs can still cause hypophysitis.
How can I tell if my symptoms may be hypophysitis?
Symptoms can include unusual fatigue or weakness, headache, nausea, loss of appetite, dizziness when standing, and confusion. Because these symptoms can resemble cancer or chemotherapy effects, report new or worsening symptoms to your oncology team, especially severe weakness, fainting, or confusion.
Can an MRI miss immunotherapy-related hypophysitis?
Doctors usually combine early-morning blood tests for ACTH, cortisol, and thyroid hormones with a contrast-enhanced MRI of the pituitary area. A normal MRI does not rule out hypophysitis, particularly in people taking PD-1 inhibitors, so hormone results and symptoms remain important.
Will pituitary hormone problems from hypophysitis go away?
Pituitary damage from hypophysitis often does not fully recover, especially when it affects ACTH, the signal that helps the body make cortisol. Many people therefore need long-term hormone replacement, with the exact plan based on repeat testing and their care team's advice.
What should I do if I become sick while taking hydrocortisone?
If you have adrenal insufficiency, your clinician should give you a written sick-day plan explaining how to adjust hydrocortisone during fever, infection, injury, or procedures. Seek emergency care if vomiting or diarrhea prevents you from keeping medicine down, or if you become severely confused, weak, or faint, and tell responders you have adrenal insufficiency.
Can I keep receiving immunotherapy after developing hypophysitis?
Many people can stabilize with hormone replacement and continue or later restart immunotherapy, but the timing depends on symptom control, hormone treatment, and the cancer plan. Do not stop or restart cancer treatment on your own; make the decision with your oncology and endocrinology teams.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific hormone deficiencies (e.g., ACTH, TSH, LH/FSH) have my blood tests confirmed?
  2. 2.Is my pituitary gland enlarged on the MRI, and are there signs of pressure on my optic nerves?
  3. 3.Since my adrenal-axis deficiency is often long-term, what is my long-term plan for hormone replacement?
  4. 4.Can you provide a written 'sick day' protocol for how much to increase my medication if I get a fever or infection?
  5. 5.When is it safe for me to restart or continue my immunotherapy treatments?
  6. 6.Should I be carrying an emergency injectable hydrocortisone kit, and can you or a nurse show me and my caregiver how to use it?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Hypophysitis Associated with Immune Checkpoint Inhibitors.

    Corsello A, Paragliola RM, Torino F, Salvatori R

    Endocrinology and metabolism clinics of North America 2025; (54(4)):685-702 doi:10.1016/j.ecl.2025.06.009.

    PMID: 41130657
  2. 2

    Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.

    Nguyen H, Shah K, Waguespack SG, et al.

    Endocrine-related cancer 2021; (28(7)):419-431.

    PMID: 33890870
  3. 3

    Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.

    Kotwal A

    Current opinion in endocrinology, diabetes, and obesity 2021; (28(4)):427-434 doi:10.1097/MED.0000000000000652.

    PMID: 34183541
  4. 4

    The side effects of immune checkpoint inhibitor therapy on the endocrine system.

    Goyal I, Pandey MR, Sharma R, et al.

    The Indian journal of medical research 2021; (154(4)):559-570 doi:10.4103/ijmr.IJMR_313_19.

    PMID: 35435341
  5. 5

    Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management.

    SirDeshpande P, Hegde SBS, Akhtar H

    Cureus 2025; (17(12)):e98717 doi:10.7759/cureus.98717.

    PMID: 41510421
  6. 6

    Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.

    Fukuda I

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2023; (90(2)):149-156 doi:10.1272/jnms.JNMS.2023_90-215.

    PMID: 36823122
  7. 7

    Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up.

    Levy M, Abeillon J, Dalle S, et al.

    Journal of clinical medicine 2020; (9(10)) doi:10.3390/jcm9103280.

    PMID: 33066179
  8. 8

    Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.

    Kanie K, Iguchi G, Bando H, et al.

    Cancer immunology, immunotherapy : CII 2021; (70(12)):3669-3677 doi:10.1007/s00262-021-02955-y.

    PMID: 33977343
  9. 9

    Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.

    Menotti S, Giampietro A, Raia S, et al.

    Journal of personalized medicine 2023; (13(8)) doi:10.3390/jpm13081210.

    PMID: 37623461
  10. 10

    A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.

    de Filette J, Andreescu CE, Cools F, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2019; (51(3)):145-156 doi:10.1055/a-0843-3366.

    PMID: 30861560
  11. 11

    Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

    Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.

    JAMA oncology 2018; (4(2)):173-182 doi:10.1001/jamaoncol.2017.3064.

    PMID: 28973656
  12. 12

    MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.

    Kurokawa R, Ota Y, Gonoi W, et al.

    AJNR. American journal of neuroradiology 2020; (41(9)):1683-1689 doi:10.3174/ajnr.A6692.

    PMID: 32763900
  13. 13

    Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.

    Deligiorgi MV, Liapi C, Trafalis DT

    Expert opinion on biological therapy 2021; (21(8)):1097-1120 doi:10.1080/14712598.2021.1869211.

    PMID: 33393372
  14. 14

    Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis.

    Yang L, Zhang Y, Chen X, et al.

    Clinical endocrinology 2024; (101(2)):130-139 doi:10.1111/cen.15075.

    PMID: 38753540
  15. 15

    Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.

    Johnson J, Goldner W, Abdallah D, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(3)):281-287 doi:10.6004/jnccn.2022.7098.

    PMID: 36828029
  16. 16

    Adrenal Failure: An Evidence-Based Diagnostic Approach.

    Shaikh S, Nagendra L, Shaikh S, Pappachan JM

    Diagnostics (Basel, Switzerland) 2023; (13(10)) doi:10.3390/diagnostics13101812.

    PMID: 37238296
  17. 17

    Adrenal Insufficiency-Induced Delirium Following Gastrectomy in a Patient With Gastric Cancer Treated With Nivolumab, Immune Checkpoint Inhibitors: A Case Report.

    Yamada K, Sasaki T, Owada T, et al.

    Neuropsychopharmacology reports 2025; (45(4)):e70072 doi:10.1002/npr2.70072.

    PMID: 41220134
  18. 18

    Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors.

    Yamauchi I, Yabe D

    European thyroid journal 2025; (14(1)).

    PMID: 39792969
  19. 19

    Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case.

    Bi Y, Adam S, Chatzimavridou V, et al.

    Endocrine oncology (Bristol, England) 2022; (2(1)):K5-K9 doi:10.1530/EO-21-0023.

    PMID: 37435468
  20. 20

    Magnetic resonance imaging features of hypophysitis in patients with cancer treated with immune checkpoint inhibitors.

    Angelousi A, Asimakopoulou S, Bourgioti C, et al.

    Journal of neuroendocrinology 2026; (38(1)):e70116 doi:10.1111/jne.70116.

    PMID: 41243162
  21. 21

    [Endocrine side effects of cancer immunotherapy].

    Kroiß M, Schilling B, Deutschbein T

    Deutsche medizinische Wochenschrift (1946) 2020; (145(24)):1736-1741 doi:10.1055/a-1140-2920.

    PMID: 33254246
  22. 22

    High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial.

    Theiler-Schwetz V, Trummer C, Schmitt L, et al.

    Annals of medicine 2025; (57(1)):2453829 doi:10.1080/07853890.2025.2453829.

    PMID: 39862267
  23. 23

    Adrenal insufficiency.

    Husebye ES, Pearce SH, Krone NP, Kämpe O

    Lancet (London, England) 2021; (397(10274)):613-629 doi:10.1016/S0140-6736(21)00136-7.

    PMID: 33484633
  24. 24

    Perioperative glucocorticoid management based on current evidence.

    Seo KH

    Anesthesia and pain medicine 2021; (16(1)):8-15 doi:10.17085/apm.20089.

    PMID: 33445232
  25. 25

    Diarrhea-An uncommon presentation of tertiary adrenal insufficiency following heart transplantation.

    Sikanderkhel S, Choudhry MW, Valentine V, et al.

    Journal of cardiac surgery 2017; (32(8)):522-525 doi:10.1111/jocs.13175.

    PMID: 28670701
  26. 26

    Hypophysitis Induced by Tislelizumab: A Case Report of Somnolence and Delirium with Elevated Eosinophils.

    Hu F, Lou N, Wu G

    The American journal of case reports 2025; (26()):e948143 doi:10.12659/AJCR.948143.

    PMID: 41277011

This page is for informational purposes only and does not constitute medical advice. Your oncology and endocrinology teams should interpret your hormone tests, adjust replacement medicine, and advise when immunotherapy can continue.

Get notified when new evidence is published on Immunotherapy induced hypophysitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.